• Fulfilling

    Potential™

    With the Science of Enzymes

  • Fulfilling

    Potential™

    In the Treatment of 

    Gastrointestinal and Rare Diseases

  • Helping

    Patients

    Fulfill Their Potential

News & Media

Alcresta Therapeutics Announces Publication of Consensus Statement Supporting Access to RELiZORB®

Jun 25, 2019

Warren, N.J. – June 25, 2019 – Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the publication of a consensus statement supporting the clinical outcomes of RELiZORB® (immobilized lipase cartridge) and advocating for improved payer coverage and patient access.

Read More

Alcresta Therapeutics Announces Appointment of Daniel Orlando as Chief Executive Officer

Jun 17, 2019

Warren, N.J. – June 17, 2019 – Alcresta Therapeutics Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the appointment of Daniel Orlando as its Chief Executive Officer (CEO) and member of the Board of Directors effective June 17, 2019.

Read More

Alcresta Therapeutics Announces that RELiZORB® iMMOBILIZED LIPASE CARTRIDGE has been Issued a Permanent Medicare Billing Code (B4105) by the Centers for Medicare and Medicaid Services (CMS)

Jan 03, 2019
  • Permanent B-Code for RELiZORB takes effect January 1, 2019
  • Updated coverage and pricing indicators will expand access to many patients

WARREN, N.J. – December 27, 2018 – Alcresta Therapeutics, Inc. announced the issuance of a permanent and unique billing code by the Centers for Medicare and Medicaid Services (CMS) for RELiZORB. RELiZORB is an in-line digestive enzyme cartridge and is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.

Read More